NCT02958397Unknown1 期
A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies
Southwest Hospital, China1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2016年10月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Adverse Events That Are Related to Treatment
研究概览
简要总结
The overall purpose of this study is to explore the therapeutic effect of CD33-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Myeloid Malignancies.
详细描述
Great progress has been made in the treatment of relapsed and refractory B cell malignancies with CD19-targeted CAR-T cells. However, for myeloid malignancies, which has higher morbidity, trials of CAR-T is few. CD33 is expressed on most myeloid leukemia cells so it is a ideal target for CAR-T. This trial is designed and conducted to test the safety and effectiveness of CD33-targeted CAR-T.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •CD33-expressing myeloid malignancy must be assured and must be relapsed or refractory disease. According to current traditional therapies, there must be no available alternative curative therapies and subjects must be either ineligible for allogeneic stem cell transplant (SCT), have refused SCT, or have disease activity that prohibits SCT at this time.
- •Patients enrolled must have an evaluated score above 60 with KPS.
- •CD33 expression of the malignant cells must be detected by immunohistochemistry or by flow cytometry.
- •Gender is not limited, age from 14 years to 75 years.
- •Patients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.
- •Patients are expected to survive for more than 3 months by their physicians at the time of enrollment.
- •Adequate absolute CD3 count estimated need to be assured for obtaining target cell dose based on dosage cohorts.
- •Subjects with the following CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia, such as cranial nerve palsy:
- •CNS 1, defined as absence of blasts in cerebral spinal fluid (CSF) on cytospin preparation, regardless of the number of WBCs; CNS 2, defined as presence of < 5/uL WBCs in CSF and cytospin positive for blasts, or > 5/uL WBCs but negative by Steinherz/Bleyer algorithm CNS3 with marrow disease who has failed salvage systemic and intensive IT chemotherapy (and therefore not eligible for radiation)
- •Ability to give informed consent.
- •Cardiac function: Left ventricular ejection fraction greater than or equal to 40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO.
- •Renal function: Creatinine level of peripheral blood is required no greater than 133umol/L.
- •Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus.
- •Patients with history of allogeneic stem cell transplantation are eligible if there is no evidence of active GVHD and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.
- •Patients volunteer to participate in the research.
排除标准
- •Evident signs suggesting that patients are potentially allergic to cytokines.
- •Frequent infection history and recent infection is uncontrolled.
- •Patients with concomitant genetic syndrome: patients with Down syndrome, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome
- •Active acute or chronic graft-versus-host disease (GVHD) or requirement of immunosuppressant medications for GVHD within 4 weeks of enrollment.
- •Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. For additional details regarding use of steroid and immunosuppressant medications.
- •Pregnancy and nursing females.
- •HIV infection.
- •Active hepatitis B or active hepatitis C.
- •Participation in a prior investigational study within 4 weeks prior to enrollment or longer if required by local regulation. Participation in non-therapeutic research studies is allowed.
- •Class III/IV cardiovascular disability according to the New York Heart Association Classification.
- •Patients with a known history or prior diagnosis of other serious immunologic, malignant or inflammatory disease.
- •Other situations we think not eligible for participation in the research.
研究组 & 干预措施
Myeloid Malignancies
Experimental
The trial will be conducted in a manner of simon two-stage design with anti-CD33-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
干预措施: Anti-CD33-CAR-transduced T cells (Biological)
结局指标
主要结局
Adverse Events That Are Related to Treatment
时间窗: 3 years
Determine the toxicity profile of the CD33 targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.
次要结局
- In vivo existence of Anti-CD33 CAR-T cells(3 years)
- Reaction Rate of Treatment(3 years)
研究者
Shiqi Li
Principal Investigator of Biotherapy Center
Southwest Hospital, China
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
A Clinical Research of CD123-Targeted CAR-T in Myeloid MalignanciesLeukemiaNCT02937103Southwest Hospital, China45
Unknown
1 期
A Clinical Research of CD30-Targeted CAR-T in Lymphocyte MalignanciesLymphomaLeukemiaNCT02958410Southwest Hospital, China45
招募中
1 期
A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT06762132Zhejiang University27
Unknown
1 期
A Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesLeukemiaLymphomaNCT02935153Southwest Hospital, China45
招募中
1 期
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AMLAML, Adult RecurrentAML, AdultAcute Myeloid LeukemiaAMLNCT06420063Essen Biotech85